全文获取类型
收费全文 | 32223篇 |
免费 | 1876篇 |
国内免费 | 155篇 |
专业分类
耳鼻咽喉 | 321篇 |
儿科学 | 781篇 |
妇产科学 | 799篇 |
基础医学 | 4740篇 |
口腔科学 | 1884篇 |
临床医学 | 2719篇 |
内科学 | 7173篇 |
皮肤病学 | 981篇 |
神经病学 | 2803篇 |
特种医学 | 542篇 |
外科学 | 2591篇 |
综合类 | 128篇 |
一般理论 | 21篇 |
预防医学 | 3650篇 |
眼科学 | 523篇 |
药学 | 2554篇 |
中国医学 | 192篇 |
肿瘤学 | 1852篇 |
出版年
2024年 | 42篇 |
2023年 | 384篇 |
2022年 | 872篇 |
2021年 | 1534篇 |
2020年 | 868篇 |
2019年 | 1250篇 |
2018年 | 1516篇 |
2017年 | 1009篇 |
2016年 | 961篇 |
2015年 | 1196篇 |
2014年 | 1570篇 |
2013年 | 1939篇 |
2012年 | 2958篇 |
2011年 | 3116篇 |
2010年 | 1547篇 |
2009年 | 1298篇 |
2008年 | 2142篇 |
2007年 | 2080篇 |
2006年 | 1801篇 |
2005年 | 1580篇 |
2004年 | 1370篇 |
2003年 | 1151篇 |
2002年 | 1001篇 |
2001年 | 110篇 |
2000年 | 64篇 |
1999年 | 94篇 |
1998年 | 134篇 |
1997年 | 128篇 |
1996年 | 82篇 |
1995年 | 64篇 |
1994年 | 66篇 |
1993年 | 48篇 |
1992年 | 44篇 |
1991年 | 29篇 |
1990年 | 23篇 |
1989年 | 20篇 |
1988年 | 16篇 |
1987年 | 14篇 |
1986年 | 13篇 |
1985年 | 12篇 |
1984年 | 12篇 |
1983年 | 12篇 |
1982年 | 15篇 |
1981年 | 9篇 |
1980年 | 13篇 |
1978年 | 6篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1973年 | 5篇 |
1972年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
111.
Aránzazu Caballero-Marcos Magdalena Salcedo Roberto Alonso-Fernández Manuel Rodríguez-Perálvarez María Olmedo Javier Graus Morales Valentín Cuervas-Mons Alba Cachero Carmelo Loinaz-Segurola Mercedes Iñarrairaegui Lluís Castells Sonia Pascual Carmen Vinaixa-Aunés Rocío González-Grande Alejandra Otero Santiago Tomé Javier Tejedor-Tejada José María Álamo-Martínez Luisa González-Diéguez Flor Nogueras-Lopez Gerardo Blanco-Fernández Gema Muñoz-Bartolo Francisco Javier Bustamante Emilio Fábrega Mario Romero-Cristóbal Rosa Martin-Mateos Julia Del Rio-Izquierdo Ana Arias-Milla Laura Calatayud Alberto A. Marcacuzco-Quinto Víctor Fernández-Alonso Concepción Gómez-Gavara Jordi Colmenero Patricia Muñoz José A. Pons the Spanish Society of Liver Transplantation 《American journal of transplantation》2021,21(8):2876-2884
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline. 相似文献
112.
Escalante-Mañe Ana M. Hernández-Nuñez Emanuel Méndez-Novelo Roger I. Giácoman-Vallejos Germán González-Sánchez Avel A. Quintanilla-Mena Mercedes A. Romellón-Orozco Mariana E. Puch-Hau Carlos 《Bulletin of environmental contamination and toxicology》2022,108(3):526-531
Bulletin of Environmental Contamination and Toxicology - We report the chemical characterisation and toxic effects of municipal solid waste landfill leachates on the embryonic development of Danio... 相似文献
113.
114.
Fabrício Silveira Ana Luísa Martins Paulo Gadelha Rmulo Paes-Sousa 《Bulletin of the World Health Organization》2021,99(3):228
The extended scope and complexity of the United Nations 2030 agenda entail important challenges for the operationalization of the health-related sustainable development goal (SDG) indicators. Divergences in concepts, agendas and implementation strategies among institutions have fostered the parallel development of alternative and concurrent indicators. We aim to determine the convergences and divergences between five key institutions: the Global Burden of Disease Study (GBD), the Pan American Health Organization, the Sustainable Development Solutions Network, the World Bank and the World Health Organization (WHO). Of the 104 health-related indicators listed by these five institutions, 60 are consistent with official Inter-agency and Expert Group SDG indicators. Our analysis considers the indicators included, and the themes these indicators cover, in each institution list and each institution online platform. We quantified convergence in indicators between the institutions themselves, but also between the institutions and the official Inter-agency and Expert Group. Our results indicate important divergences; only 22 of the 60 indicators are included in the lists of all five institutions. The level of adoption of the official metrics varies from 40.5% (15/(47−10)) for the GBD to 86.2% (25/(29−0)) for the World Bank. WHO, the official curator of the Inter-agency and Expert Group SDG indicators, is only convergent with the official metrics by 72.1% (31/(45−2)). Our analysis, and the resulting awareness of the differences, potentialities and limitations of indicators and platforms, provides important contributions to enable the achievement of the health-related SDGs and deliver the promise of the 2030 agenda. 相似文献
115.
116.
Louise B. Russell Sun-Young Kim Cristiana Toscano Ben Cosgriff Ruth Minamisava Ana Lucia Andrade Colin Sanderson Anushua Sinha 《Vaccine》2021,39(1):158-166
BackgroundThis paper compares cost-effectiveness results from two models of maternal immunization to prevent pertussis in infants in Brazil, one static, one dynamic, to explore when static models are adequate for public health decisions and when the extra effort required by dynamic models is worthwhile.MethodsWe defined two scenarios to explore key differences between static and dynamic models, herd immunity and time horizon. Scenario 1 evaluates the incremental cost/DALY of maternal acellular pertussis (aP) immunization as routine infant vaccination coverage ranges from low/moderate up to, and above, the threshold at which herd immunity begins to eliminate pertussis. Scenario 2 compares cost-effectiveness estimates over the models’ different time horizons. Maternal vaccine prices of $9.55/dose (base case) and $1/dose were evaluated.ResultsThe dynamic model shows that maternal immunization could be cost-saving as well as life-saving at low levels of infant vaccination coverage. When infant coverage reaches the threshold range (90–95%), it is expensive: the dynamic model estimates that maternal immunization costs $2 million/DALY at infant coverage > 95% and maternal vaccine price of $9.55/dose; at $1/dose, cost/DALY is $200,000. By contrast, the static model estimates costs/DALY only modestly higher at high than at low infant coverage. When the models’ estimates over their different time horizons are compared at infant coverage < 90–95%, their projections fall in the same range.ConclusionsStatic models may serve to explore an intervention’s cost-effectiveness against infectious disease: the direction and principal drivers of change were the same in both models. When, however, an intervention too small to have significant herd immunity effects itself, such as maternal aP immunization, takes place against a background of vaccination in the rest of the population, a dynamic model is crucial to accurate estimates of cost-effectiveness. This finding is particularly important in the context of widely varying routine infant vaccination rates globally.Clinical Trial registryClinical Trial registry name and registration number: Not applicable. 相似文献
117.
118.
Dayana A. Delgado Meytal Chernoff Lei Huang Lin Tong Lin Chen Farzana Jasmine Justin Shinkle Shelley A. Cole Karin Haack Jack Kent Jason Umans Lyle G. Best Heather Nelson Donald Vander Griend Joseph Graziano Muhammad G. Kibriya Ana Navas-Acien Margaret R. Karagas Habibul Ahsan Brandon L. Pierce 《Environmental health perspectives》2021,129(5)
119.
Samuel Cibulski Thais Fumaco Teixeira Ana Paula Muterle Varela Matheus Fabião de Lima Gabriela Casanova Yuri Mangueira Nascimento Josean Fechine Tavares Marcelo Sobral da Silva Patrícia Sesterheim Diogo Onofre Souza Paulo Michel Roehe Fernando Silveira 《Vaccine》2021,39(3):571-579
Vaccine adjuvants are compounds that enhance/prolong the immune response to a co-administered antigen. Saponins have been widely used as adjuvants for many years in several vaccines – especially for intracellular pathogens – including the recent and somewhat revolutionary malaria and shingles vaccines. In view of the immunoadjuvant potential of Q. brasiliensis saponins, the present study aimed to characterize the QB-80 saponin-rich fraction and a nanoadjuvant prepared with QB-80 and lipids (IMXQB-80). In addition, the performance of such adjuvants was examined in experimental inactivated vaccines against Zika virus (ZIKV). Analysis of QB-80 by DI-ESI-ToF by negative ion electrospray revealed over 29 saponins that could be assigned to known structures existing in their congener Q. saponaria, including the well-studied QS-21 and QS-7. The QB-80 saponins were a micrOTOF able to self-assembly with lipids in ISCOM-like nanoparticles with diameters of approximately 43 nm, here named IMXQB-80. Toxicity assays revealed that QB-80 saponins did present some haemolytical and cytotoxic potentials; however, these were abrogated in IMXQB-80 nanoparticles. Regarding the adjuvant activity, QB-80 and IMXQB-80 significantly enhanced serum levels of anti-Zika virus IgG and subtypes (IgG1, IgG2b, IgG2c) as well as neutralized antibodies when compared to an unadjuvanted vaccine. Furthermore, the nanoadjuvant IMXQB-80 was as effective as QB-80 in stimulating immune responses, yet requiring fourfold less saponins to induce the equivalent stimuli, and with less toxicity. These findings reveal that the saponin fraction QB-80, and particularly the IMXQB-80 nanoadjuvant, are safe and capable of potentializing immune responses when used as adjuvants in experimental ZIKV vaccines. 相似文献
120.
André Beate Canhão Helena Espnes Geir A. Rodrigues Ana Maria Ferreira Gregorio Maria Joao Nguyen Camilla Sousa Rute Grønning Kjersti 《Zeitschrift fur Gesundheitswissenschaften》2021,29(6):1373-1378
Journal of Public Health - Adolescents’ sleep duration has decreased over the past century; this is mainly caused by problems with falling asleep. Short sleep duration, poor sleep quality,... 相似文献